Melanotan I is a synthetic analogue of the natural peptide alpha-MSH. It acts mainly as a melanocortin-1 receptor (MC1R) agonist, a pathway that influences melanin production and skin pigmentation.

What does research suggest about Melanotan I?

The melanocortin pathway and its pigmentation effects are well characterized in preclinical animal studies. A related compound, afamelanotide, has clinical evidence supporting a specific rare condition, but broad human evidence for research-market Melanotan I itself is limited.

Is Melanotan I approved or legal?

Research-market Melanotan I is not an approved medicine. A related compound, afamelanotide, is approved in some regions for a narrow rare-disease indication under prescription. Legal status of the research-market peptide varies by country and its sale for human use is often restricted.

Unregulated research-market use carries risks and has not been evaluated for general use. A notable concern is its effect on existing moles and freckles, so dermatological monitoring is emphasized. It is not a substitute for medical care, and a clinician should be consulted.

What are the reported side effects of Melanotan I?

Commonly reported effects include nausea and darkening of existing moles and freckles. Because it can change the appearance of pigmented lesions, any new or changing mole warrants professional dermatological evaluation.

How is Melanotan I different from Melanotan II?

Melanotan I is a more selective MC1R-focused alpha-MSH analogue tied to the approved drug afamelanotide. Melanotan II is a separate, non-selective melanocortin agonist that regulators have repeatedly flagged with safety warnings.

Is Melanotan I the same thing as the approved drug afamelanotide?

They share the same underlying molecule, but they are not interchangeable in practice. Afamelanotide is a regulated, slow-release implant approved for one rare condition and given under medical supervision. Research-market Melanotan I sold as a powder is not that approved product, is not quality-controlled to pharmaceutical standards, and is not evaluated for general use. Treating the two as equivalent is a common misconception.

How is Melanotan I different from Melanotan II?

They are separate compounds. Melanotan I (afamelanotide) is a more selective melanocortin-1 receptor agonist tied to an approved medicine, while Melanotan II is a non-selective agonist that acts on additional melanocortin receptors and has drawn multiple regulator safety warnings. People often conflate the two names, but their receptor selectivity, history, and regulatory standing differ.

Why does pigmentation research pay attention to the melanocortin-1 receptor?

The melanocortin-1 receptor sits at the center of how skin produces melanin in response to the natural hormone alpha-MSH. Because Melanotan I is a longer-acting analogue of that hormone, it became a research tool for studying pigmentation biology and photoprotection pathways. This is why the molecule is discussed in a scientific context rather than as a cosmetic product.

Where can I buy Melanotan I and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Pigmentation

Buy Melanotan I – Vendors, Prices, Testing and Evidence

Buy Melanotan I

Also known as: Afamelanotide (related)

Evidence grade B — Human, limitedRisk flag

Short answer

A melanocortin agonist related to an approved medicine. Research-market use is unregulated and carries risks.

Where can you buy Melanotan I?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

Melanotan I is a synthetic analogue of alpha-MSH affecting pigmentation.

What is not established?

The related approved drug has clinical evidence for a specific rare condition; general research-market use does not.

Safety

Unregulated research-market use carries risks including effects on existing moles; dermatological monitoring matters.

Regulatory status

A related compound (afamelanotide) is an approved medicine for a rare condition; research-market Melanotan I is not.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy Melanotan I: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	Melanotan I research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

Melanotan I research product

Code PEPTIDES10 −10% · discount code details

What is it?

Melanotan I is a synthetic analogue of alpha-MSH affecting pigmentation.

Research and evidence

Melanotan I is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide that regulates skin pigmentation. It works chiefly as an agonist at the melanocortin-1 receptor (MC1R), the receptor on melanocytes that governs melanin production. By activating this pathway, Melanotan I can shift the balance toward eumelanin synthesis, the darker, more photoprotective form of melanin. Because of this mechanism, it is frequently discussed in the context of pigmentation and photoprotection. It is important to distinguish Melanotan I from Melanotan II: the latter is a separate, non-selective melanocortin agonist that regulators have repeatedly flagged for safety concerns.

The most significant thing to understand about Melanotan I is its regulatory picture. A closely related compound, afamelanotide (marketed in some regions as Scenesse), has been developed and approved as a prescription medicine for a specific rare condition involving light sensitivity, where it is administered and monitored clinically. That approval reflects a defined benefit-risk assessment for one narrow indication. It does not extend to the unregulated "research-market" Melanotan I sold outside medical supervision, which has not undergone the same evaluation for general use. The melanocortin system and its pigmentation effects are well characterized in preclinical animal models, but human clinical evidence supporting broad, self-directed use of research-market Melanotan I is limited to absent.

Melanotan I is offered here as an educational reference only, not as medical advice, and this page describes no dosing, protocols, or sourcing. The honest evidence picture is mixed: mechanism is well understood, one related drug is approved for a narrow purpose, and unregulated use carries real risks. Reported side effects include nausea and darkening of existing moles and freckles. Because melanocortin agonists can alter the appearance of pigmented lesions, dermatological monitoring is a recurring theme in serious discussion of this peptide, and any change in moles is a reason to seek professional evaluation. Anyone considering pigmentation-related compounds should consult a qualified clinician.

Evidence grade: B

The related approved drug has clinical evidence for a specific rare condition; general research-market use does not. Melanocortin effects well characterised preclinically.

Human evidence

The related approved drug has clinical evidence for a specific rare condition; general research-market use does not.

Animal and preclinical evidence

Melanocortin effects well characterised preclinically.

Proposed mechanisms

Melanocortin-1 receptor agonism affecting melanin production

Safety concerns and known side effects

Unregulated research-market use carries risks including effects on existing moles; dermatological monitoring matters.

Nausea reported
Darkening of moles/freckles reported

Regulatory status

A related compound (afamelanotide) is an approved medicine for a rare condition; research-market Melanotan I is not.

Melanotan I research timeline

1980s
Researchers at the University of Arizona synthesized potent, longer-acting analogues of the natural hormone alpha-MSH while studying pigmentation, producing the compound now known as Melanotan I (afamelanotide).
1990s
Preclinical and early exploratory work characterized melanocortin-1 receptor agonism and its effect on melanin production, framing the molecule as a possible photoprotection tool.
2000s
The compound was licensed for pharmaceutical development as afamelanotide (a slow-release implant), while an unregulated 'research-market' version of Melanotan I began circulating separately from that regulated program.
early 2010s
Afamelanotide (brand name Scenesse) received European marketing authorization for the rare condition erythropoietic protoporphyria, establishing clinical evidence for that narrow indication.
late 2010s
U.S. regulators approved afamelanotide for the same rare condition, but this approval applies only to the controlled implant, not to research-market Melanotan I sold as a powder.
early 2020s
Regulators and dermatology bodies continued to distinguish the approved medicine from unregulated Melanotan I/II products, noting risks such as changes to existing moles and the need for skin monitoring.

Frequently asked questions about Melanotan I

What is Melanotan I?: Melanotan I is a synthetic analogue of the natural peptide alpha-MSH. It acts mainly as a melanocortin-1 receptor (MC1R) agonist, a pathway that influences melanin production and skin pigmentation.
What does research suggest about Melanotan I?: The melanocortin pathway and its pigmentation effects are well characterized in preclinical animal studies. A related compound, afamelanotide, has clinical evidence supporting a specific rare condition, but broad human evidence for research-market Melanotan I itself is limited.
Is Melanotan I approved or legal?: Research-market Melanotan I is not an approved medicine. A related compound, afamelanotide, is approved in some regions for a narrow rare-disease indication under prescription. Legal status of the research-market peptide varies by country and its sale for human use is often restricted.
Is Melanotan I safe?: Unregulated research-market use carries risks and has not been evaluated for general use. A notable concern is its effect on existing moles and freckles, so dermatological monitoring is emphasized. It is not a substitute for medical care, and a clinician should be consulted.
What are the reported side effects of Melanotan I?: Commonly reported effects include nausea and darkening of existing moles and freckles. Because it can change the appearance of pigmented lesions, any new or changing mole warrants professional dermatological evaluation.
How is Melanotan I different from Melanotan II?: Melanotan I is a more selective MC1R-focused alpha-MSH analogue tied to the approved drug afamelanotide. Melanotan II is a separate, non-selective melanocortin agonist that regulators have repeatedly flagged with safety warnings.
Is Melanotan I the same thing as the approved drug afamelanotide?: They share the same underlying molecule, but they are not interchangeable in practice. Afamelanotide is a regulated, slow-release implant approved for one rare condition and given under medical supervision. Research-market Melanotan I sold as a powder is not that approved product, is not quality-controlled to pharmaceutical standards, and is not evaluated for general use. Treating the two as equivalent is a common misconception.
How is Melanotan I different from Melanotan II?: They are separate compounds. Melanotan I (afamelanotide) is a more selective melanocortin-1 receptor agonist tied to an approved medicine, while Melanotan II is a non-selective agonist that acts on additional melanocortin receptors and has drawn multiple regulator safety warnings. People often conflate the two names, but their receptor selectivity, history, and regulatory standing differ.
Why does pigmentation research pay attention to the melanocortin-1 receptor?: The melanocortin-1 receptor sits at the center of how skin produces melanin in response to the natural hormone alpha-MSH. Because Melanotan I is a longer-acting analogue of that hormone, it became a research tool for studying pigmentation biology and photoprotection pathways. This is why the molecule is discussed in a scientific context rather than as a cosmetic product.
Where can I buy Melanotan I and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

PigmentationPhotoprotection context

Compare Melanotan I

Melanotan I vs Melanotan II

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10